Promising preclinical approaches to combating cancer-associated cachexia/tissue wasting
- PMID: 40492746
- DOI: 10.1097/SPC.0000000000000763
Promising preclinical approaches to combating cancer-associated cachexia/tissue wasting
Abstract
Purpose of review: To highlight promising pre-clinical work seeking to target cancer-associated tissue/muscle wasting.
Recent findings: This narrative review explores recent innovations and emerging/understudied aspects of cancer cachexia biology, highlighting representative studies across three key areas: (a) novel strategies for targeting established wasting pathways, (b) multimodal/combinatorial therapeutic approaches, and (c) mechanisms involving inter-tissue communication.
Summary: Though not exhaustive, this review highlights three key areas of pre-clinical research with the potential to inform and inspire future clinical trials aimed at mitigating cachexia and tissue wasting in cancer patients.
Keywords: cachexia; muscle wasting; preclinical targets.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Balsano R, Kruize Z, Lunardi M, et al. Transforming growth factor-beta signalling in cancer-induced cachexia: from molecular pathways to the clinics. Cells. 2022; 11:2671.
-
- Lan XQ, Deng CJ, Wang QQ, et al. The role of TGF-beta signalling in muscle atrophy, sarcopenia and cancer cachexia. Gen Comp Endocrinol 2024; 353:114513.
-
- Ozawa T, Morikawa M, Morishita Y, et al. Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice. iScience. 2021; 24:102488.
-
- Zhang Y, Dos Santos M, Huang H, et al. A molecular pathway for cancer cachexia-induced muscle atrophy revealed at single-nucleus resolution, Cell Rep 2024; 43:114587.
-
- Teixeira AF, Ten Dijke P, Zhu HJ. On-target anti-TGF-beta therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front Cell Dev Biol. 2020; 8:605.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
